Lipocine (NASDAQ:LPCN) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened

Lipocine Inc. (NASDAQ:LPCN) shares passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.28 and traded as high as $2.56. Lipocine shares last traded at $2.34, with a volume of 159,254 shares changing hands.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. Finally, Wall Street Zen lowered shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Price Performance

The stock’s fifty day moving average price is $2.29 and its 200-day moving average price is $5.53. The company has a market capitalization of $19.21 million, a price-to-earnings ratio of -1.24 and a beta of 0.48.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The business had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.16 million. Analysts anticipate that Lipocine Inc. will post -1.91 EPS for the current year.

Insider Transactions at Lipocine

In related news, CEO Mahesh V. Patel bought 25,000 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were acquired at an average price of $2.03 per share, with a total value of $50,750.00. Following the completion of the transaction, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. The trade was a 18.43% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director John W. Higuchi bought 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an average price of $2.03 per share, for a total transaction of $81,200.00. Following the acquisition, the director directly owned 203,797 shares of the company’s stock, valued at $413,707.91. This represents a 24.42% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 213,000 shares of company stock worth $434,600. 6.35% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lipocine

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC bought a new stake in Lipocine during the third quarter worth $41,000. Jane Street Group LLC acquired a new position in shares of Lipocine during the 4th quarter worth about $85,000. Dimensional Fund Advisors LP lifted its stake in Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in Lipocine during the first quarter worth about $185,000. Finally, Renaissance Technologies LLC grew its holdings in Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the period. 9.11% of the stock is owned by institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.